HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eric K Rowinsky Selected Research

exatecan (DX 8951f)

8/2005A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
1/2004A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
7/2003A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eric K Rowinsky Research Topics

Disease

85Neoplasms (Cancer)
02/2015 - 01/2002
17Neutropenia
10/2011 - 05/2002
12Colorectal Neoplasms (Colorectal Cancer)
02/2011 - 01/2002
10Exanthema (Rash)
06/2011 - 08/2004
8Fatigue
06/2011 - 07/2002
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2012 - 05/2002
7Nausea
02/2012 - 07/2002
7Disease Progression
10/2011 - 05/2003
7Breast Neoplasms (Breast Cancer)
06/2010 - 01/2003
7Diarrhea
07/2008 - 07/2002
6Adenocarcinoma
08/2012 - 01/2003
6Thrombocytopenia (Thrombopenia)
01/2011 - 07/2003
5Vomiting
02/2012 - 07/2002
4Mucositis
06/2010 - 04/2003
4Fever (Fevers)
06/2007 - 07/2002
3Pancreatic Neoplasms (Pancreatic Cancer)
08/2012 - 07/2007
3Asthenia
02/2012 - 10/2006
3Anorexia
02/2012 - 07/2002
3Sarcoma (Soft Tissue Sarcoma)
06/2011 - 08/2007
3Neoplasm Metastasis (Metastasis)
02/2010 - 01/2004
3Head and Neck Neoplasms (Head and Neck Cancer)
01/2010 - 02/2006
3Squamous Cell Carcinoma of Head and Neck
01/2010 - 02/2006
2Hematologic Neoplasms (Hematological Malignancy)
02/2010 - 09/2007
2Hyperbilirubinemia
10/2008 - 07/2003
2Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
09/2007 - 12/2004
2Renal Cell Carcinoma (Grawitz Tumor)
09/2007 - 08/2004
2Stomatitis
08/2007 - 10/2006
2Melanoma (Melanoma, Malignant)
02/2007 - 07/2002
2Febrile Neutropenia
02/2006 - 01/2006
2Lung Neoplasms (Lung Cancer)
12/2004 - 02/2003
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2003 - 01/2002
1Respiratory Insufficiency (Respiratory Failure)
10/2020
1Multiple Myeloma
10/2020

Drug/Important Bio-Agent (IBA)

18Pharmaceutical PreparationsIBA
02/2015 - 07/2002
14ErbB Receptors (EGF Receptor)IBA
02/2011 - 01/2002
10Biological ProductsIBA
02/2015 - 01/2003
10Monoclonal AntibodiesIBA
03/2010 - 01/2003
8Cetuximab (Erbitux)FDA Link
08/2012 - 03/2005
6Proteins (Proteins, Gene)FDA Link
10/2020 - 01/2002
5Paclitaxel (Taxol)FDA LinkGeneric
03/2012 - 02/2003
5Cisplatin (Platino)FDA LinkGeneric
02/2012 - 02/2003
5DNA (Deoxyribonucleic Acid)IBA
11/2010 - 01/2003
5Erlotinib Hydrochloride (CP 358,774)FDA Link
07/2010 - 07/2003
5Transaminases (Aminotransferases)IBA
06/2010 - 07/2002
4Tyrosine Kinase InhibitorsIBA
07/2010 - 05/2002
4TOR Serine-Threonine KinasesIBA
06/2010 - 06/2003
4Irinotecan (Camptosar)FDA LinkGeneric
12/2008 - 08/2004
4Sirolimus (Rapamycin)FDA Link
01/2008 - 06/2003
4Pemetrexed (MTA)FDA Link
05/2007 - 01/2006
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2012 - 02/2007
3GemcitabineFDA Link
08/2012 - 10/2003
3Carboplatin (JM8)FDA LinkGeneric
03/2012 - 12/2006
3TrabectedinIBA
05/2010 - 01/2002
3troxacitabineIBA
12/2009 - 01/2002
3LigandsIBA
12/2005 - 01/2004
3Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2005 - 02/2003
3CamptothecinIBA
11/2005 - 01/2003
3exatecan (DX 8951f)IBA
08/2005 - 07/2003
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2004 - 01/2003
3PlatinumIBA
08/2004 - 05/2002
2Bexarotene (LGD1069)FDA Link
03/2012 - 02/2012
2NucleosidesIBA
02/2012 - 01/2002
2Hormones (Hormone)IBA
12/2011 - 08/2004
2cixutumumabIBA
12/2011 - 09/2007
2Insulin-Like PeptidesIBA
12/2011 - 11/2010
2Doxorubicin (Adriamycin)FDA LinkGeneric
10/2011 - 02/2003
2Sorafenib (BAY 43-9006)FDA Link
06/2011 - 09/2005
2EnzymesIBA
01/2011 - 07/2002
2temsirolimusFDA Link
06/2010 - 10/2006
2Immunoglobulin G (IgG)IBA
03/2010 - 02/2010
2Phosphotransferases (Kinase)IBA
02/2010 - 07/2003
2Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
02/2010 - 02/2010
2Cytotoxins (Cytolysins)IBA
02/2010 - 05/2003
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2010 - 01/2002
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
02/2010 - 09/2007
2taxaneIBA
01/2009 - 10/2003
2Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2008 - 10/2006
2Thymidylate SynthaseIBA
12/2008 - 11/2004
2CreatinineIBA
10/2008 - 01/2006
2Lapatinib (GW572016)FDA Link
07/2008 - 08/2007
2AntibodiesIBA
09/2007 - 07/2004
2tetracycline CMT-3IBA
08/2007 - 10/2004
2VitaminsIBA
01/2007 - 02/2006
2Growth Factor ReceptorsIBA
09/2005 - 06/2003
2Docetaxel (Taxotere)FDA Link
11/2004 - 08/2004
2Biomarkers (Surrogate Marker)IBA
08/2004 - 08/2004
2Epidermal Growth Factor (EGF)IBA
08/2004 - 03/2004
2Fluorouracil (Carac)FDA LinkGeneric
01/2004 - 04/2003
2Farnesyltranstransferase (Farnesyltransferase)IBA
10/2003 - 10/2003
2Trastuzumab (Herceptin)FDA Link
10/2003 - 01/2003
2Gefitinib (Iressa)FDA Link
01/2003 - 05/2002
2Topotecan (Hycamtin)FDA LinkGeneric
05/2002 - 01/2002
1Deubiquitinating EnzymesIBA
10/2020
1Bortezomib (Velcade)FDA Link
10/2020
1VLX1570IBA
10/2020

Therapy/Procedure

22Therapeutics
08/2012 - 01/2002
9Drug Therapy (Chemotherapy)
02/2012 - 01/2003
4Radiotherapy
01/2010 - 03/2004
2Drug Tapering
06/2010 - 10/2006
2Aftercare (After-Treatment)
06/2007 - 07/2003